Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × Clarithromycin × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neoplasms, Plasma Cell 1 Multiple Myeloma 1

Interventions

Dexamethasone 24 Cyclophosphamide 21 venetoclax 17 Lenalidomide 13 fludarabine 12 Bortezomib 12 pembrolizumab 11 Cytarabine 11 Carboplatin 10 Calcium Dobesilate 10 Rituximab 9 pomalidomide 7 Nivolumab 7 Gemcitabine 7 Azacitidine 7 fludarabine phosphate 6 carfilzomib 6 blinatumomab 6 selinexor 5 obinutuzumab 5 ibrutinib 5 daratumumab 5 Temozolomide 5 Decitabine 5 Cisplatin 5 Bendamustine Hydrochloride 5 elotuzumab 4 Methotrexate 4 Etoposide 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02343042 2025-12-22

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡